These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 24482024

  • 1. Draining the edema: a new role for aquaretics?
    Bockenhauer D.
    Pediatr Nephrol; 2014 May; 29(5):767-9. PubMed ID: 24482024
    [Abstract] [Full Text] [Related]

  • 2. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.
    Shimizu M, Ishikawa S, Yachi Y, Muraoka M, Tasaki Y, Iwasaki H, Kuroda M, Ohta K, Yachie A.
    Pediatr Nephrol; 2014 May; 29(5):915-7. PubMed ID: 24240509
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.
    Saimiya M, Kaku Y, Nishimura M.
    CEN Case Rep; 2021 Nov; 10(4):523-526. PubMed ID: 33904139
    [Abstract] [Full Text] [Related]

  • 4. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
    Takada T, Masaki T, Hoshiyama A, Toki T, Kamata Y, Shichiri M.
    Nephrology (Carlton); 2018 Sep; 23(9):883-886. PubMed ID: 29665203
    [Abstract] [Full Text] [Related]

  • 5. Is tolvaptan indicated for refractory oedema in nephrotic syndrome?
    Park ES, Huh YS, Kim GH.
    Nephrology (Carlton); 2015 Feb; 20(2):103-6. PubMed ID: 25619649
    [Abstract] [Full Text] [Related]

  • 6. Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome.
    Tanaka A, Nakamura T, Sato E, Ueda Y, Node K.
    Intern Med; 2017 Feb; 56(2):191-196. PubMed ID: 28090051
    [Abstract] [Full Text] [Related]

  • 7. Pharmacology of vasopressin antagonists.
    Costello-Boerrigter LC, Boerrigter G, Burnett JC.
    Heart Fail Rev; 2009 Jun; 14(2):75-82. PubMed ID: 18766438
    [Abstract] [Full Text] [Related]

  • 8. V2 receptor antagonism with tolvaptan in heart failure.
    Costello-Boerrigter LC, Boerrigter G, Burnett JC.
    Expert Opin Investig Drugs; 2007 Oct; 16(10):1639-47. PubMed ID: 17922627
    [Abstract] [Full Text] [Related]

  • 9. Perspectives on edema in childhood nephrotic syndrome.
    Teoh CW, Robinson LA, Noone D.
    Am J Physiol Renal Physiol; 2015 Oct 01; 309(7):F575-82. PubMed ID: 26290369
    [Abstract] [Full Text] [Related]

  • 10. Furosemide and albumin for the treatment of nephrotic edema: a systematic review.
    Hedin E, Bijelić V, Barrowman N, Geier P.
    Pediatr Nephrol; 2022 Aug 01; 37(8):1747-1757. PubMed ID: 35239032
    [Abstract] [Full Text] [Related]

  • 11. Nephrotic syndrome complicated by idiopathic central diabetes insipidus.
    Konomoto T, Tanaka E, Imamura H, Orita M, Sawada H, Nunoi H.
    Pediatr Nephrol; 2014 May 01; 29(5):927-30. PubMed ID: 24408226
    [Abstract] [Full Text] [Related]

  • 12. Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications.
    Doucet A, Favre G, Deschênes G.
    Pediatr Nephrol; 2007 Dec 01; 22(12):1983-90. PubMed ID: 17554565
    [Abstract] [Full Text] [Related]

  • 13. AVP receptor antagonists as aquaretics: review and assessment of clinical data.
    Verbalis JG.
    Cleve Clin J Med; 2006 Sep 01; 73 Suppl 3():S24-33. PubMed ID: 16970150
    [Abstract] [Full Text] [Related]

  • 14. Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome.
    Tanaka A, Nakamura T, Sato E, Node K.
    Int J Cardiol; 2016 May 01; 210():1-3. PubMed ID: 26921537
    [No Abstract] [Full Text] [Related]

  • 15. [Molecular mechanism of edema formation in nephrotic syndrome].
    Deschênes G, Guigonis V, Doucet A.
    Arch Pediatr; 2004 Sep 01; 11(9):1084-94. PubMed ID: 15351000
    [Abstract] [Full Text] [Related]

  • 16. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I.
    Expert Rev Gastroenterol Hepatol; 2014 Jul 01; 8(5):461-70. PubMed ID: 24678622
    [Abstract] [Full Text] [Related]

  • 17. Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease.
    Imamura T.
    Int Heart J; 2014 Jul 01; 55(6):482-3. PubMed ID: 25318555
    [No Abstract] [Full Text] [Related]

  • 18. Anti-edematous effects of tolvaptan in experimental rodent models.
    Miyazaki T, Sakamoto Y, Yamashita T, Ohmoto K, Fujiki H.
    Cardiovasc Drugs Ther; 2011 Dec 01; 25 Suppl 1():S77-82. PubMed ID: 22120096
    [Abstract] [Full Text] [Related]

  • 19. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure.
    Sato E, Nakamura T, Amaha M, Nomura M, Matsumura D, Yamagishi H, Ono Y, Ueda Y.
    Int Heart J; 2014 Dec 01; 55(6):533-8. PubMed ID: 25318553
    [Abstract] [Full Text] [Related]

  • 20. Hyponatremia and cyst growth in neonatal polycystic kidney disease: a case for aquaretics?
    Bockenhauer D.
    Pediatr Nephrol; 2017 May 01; 32(5):721-723. PubMed ID: 28194573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.